Cargando…

Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver

BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is commonly observed in patients with type 2 diabetes, and thiazolidinediones (TZD) are considered a potential therapy for NASH. Although TZD increase insulin sensitivity and partially reduce steatosis and alanine aminotransferase, the effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Samuel M., Pusec, Carolina M., Norris, Gregory H., De Jesus, Adam, Diaz-Ruiz, Alberto, Muratalla, Jose, Sarmento-Cabral, Andre, Guzman, Grace, Layden, Brian T., Cordoba-Chacon, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005819/ https://www.ncbi.nlm.nih.gov/pubmed/33444819 http://dx.doi.org/10.1016/j.jcmgh.2021.01.003

Ejemplares similares

HepatocyteGHR/STAT5b Signaling Protects Against Liver Injury in NAFLD/NASH Mice Models Independent of Steatosis
por: del Río-Moreno, Mercedes, et al.
Publicado: (2021)

OR14-05 Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice
por: Muratalla, Jose T, et al.
Publicado: (2020)

Loss of Hepatocyte-Specific PPARγ Expression Ameliorates Early Events of Steatohepatitis in Mice Fed the Methionine and Choline-Deficient Diet
por: Cordoba-Chacon, Jose
Publicado: (2020)

Liver-specific overexpression of HKDC1 increases hepatocyte size and proliferative capacity
por: Pusec, Carolina M., et al.
Publicado: (2023)

SAT-152 Loss of Hepatocyte PPARγ Expression Ameliorates Steatosis in Mice Fed a High-Fat, Cholesterol, and Fructose Diet, but Not in Mice Fed a Methionine- and Choline-Deficient Diet
por: Tummala, Apoorva, et al.
Publicado: (2019)

Rosiglitazone activation of PPARγ suppresses fractalkine signaling
por: Wan, Yihong, et al.
Publicado: (2010)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis
por: Ramakers, Julian D., et al.
Publicado: (2007)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model
por: Guzeloglu, Mehmet, et al.
Publicado: (2012)

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
por: Cheng, Wing Yin, et al.
Publicado: (2016)

Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS
por: Jing, Xinyue, et al.
Publicado: (2016)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers
por: Step, Sonia E., et al.
Publicado: (2014)

Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization
por: Hu, Jiamiao, et al.
Publicado: (2018)

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study
por: GÜNDOĞDU, Burcu, et al.
Publicado: (2020)

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
por: Wu, Yanqiao, et al.
Publicado: (2020)

Rosiglitazone-Mediated Activation of PPARγ Restores HO1 Expression in the Human Preeclamptic Placenta
por: Grimaldi, Brooke, et al.
Publicado: (2023)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012)

Activation of PPARγ by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats
por: Mansour, Mahmoud, et al.
Publicado: (2009)

Retraction of “Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis”
por: Wu, Yanqiao, et al.
Publicado: (2021)

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation
por: Sánchez-Aguilar, María, et al.
Publicado: (2019)

SUN-LB52 The Protective Effects of Hepatocyte GH Receptor (GHR) Signaling Against Steatosis and Liver Injury Is Sexually Dimorphic and Autonomous of IGF1
por: Sarmento-Cabral, Andre, et al.
Publicado: (2020)

Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
por: Mao, Jing-Wei, et al.
Publicado: (2012)

Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS
por: Zhao, Zhigang, et al.
Publicado: (2011)

SAT038 Dietary Trans-10,cis-12 Conjugated Linoleic Acid Regulates Glucose Levels In Mice With Severe Insulin Resistance: Potential Effects On The Liver Via HNF4α And FOX01
por: Man Lee, Samuel, et al.
Publicado: (2023)

PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice
por: Sun, Ying, et al.
Publicado: (2013)

Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone
por: Yang, Xu-Hong, et al.
Publicado: (2015)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
por: Park, Kyeong‐Lok, et al.
Publicado: (2018)

Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Wu, Jiayi, et al.
Publicado: (2022)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue
por: Ryu, Seung Lok, et al.
Publicado: (2013)

Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model
por: Cortez, IbDanelo, et al.
Publicado: (2020)

Retracted: Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Markers, Disease
Publicado: (2023)

Review article: vascular effects of PPARs in the context of NASH
por: Guixé‐Muntet, Sergi, et al.
Publicado: (2022)

Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH
por: Bonnet, Laurianne, et al.
Publicado: (2022)

Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
por: Myint, Melissa, et al.
Publicado: (2023)

Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms
por: He, Qing, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_6061kb4pmugjfqk7os0ke2nhgf